Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020

Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has filed its Annual Report on Form 20-F for the fiscal year ending March 31, 2021, with the SEC on June 29, 2021. The report is available on Takeda's website. Additionally, Takeda has published its 2021 Annual Integrated Report, accessible online. The company emphasizes its commitment to research and development in various therapeutic areas, including Oncology and Neuroscience, while offering free hard copies of the Annual Report to shareholders upon request.

Positive

• The Annual Report contains complete audited financial statements.
• The company provides free hard copies of the Annual Report to shareholders upon request.
• Takeda maintains a strong focus on R&D in key therapeutic areas.

Negative

• None.

Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”). Takeda filed the Annual Report with the SEC on June 29, 2021, and the Annual Report can be accessed on Takeda’s website at: https://www.takeda.com/investors/sec-filings/.

In addition, Takeda will also provide a hard copy of the Annual Report, which includes its most recent complete audited financial statements free of charge to any shareholder upon request. Please contact Takeda Investor Relations by e-mail at takeda.ir.contact@takeda.com.

Additionally, Takeda also published today its 2021 Annual Integrated Report for the fiscal year ended March 31, 2021. It can be accessed on Takeda’s website at: https://air.takeda.com.

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005633/en/

FAQ

What is the filing date of Takeda's Annual Report for 2021?

Takeda filed its Annual Report on Form 20-F on June 29, 2021.

Where can I access Takeda's Annual Report?

Takeda's Annual Report can be accessed on their website at https://www.takeda.com/investors/sec-filings/.

What fiscal year does Takeda's Annual Report cover?

The Annual Report covers the fiscal year ended March 31, 2021.

Is Takeda's Annual Integrated Report available online?

Yes, Takeda's 2021 Annual Integrated Report is available at https://air.takeda.com.